Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Quantitative V gene–targeted T cell receptor sequencing as a biomarker in type 1 diabetes
Laurie G. Landry, Kristen L. Wells, Amanda M. Anderson, Kristen R. Miller, Kenneth L. Jones, Aaron W. Michels, Maki Nakayama
Laurie G. Landry, Kristen L. Wells, Amanda M. Anderson, Kristen R. Miller, Kenneth L. Jones, Aaron W. Michels, Maki Nakayama
View: Text | PDF
Research Article Immunology

Quantitative V gene–targeted T cell receptor sequencing as a biomarker in type 1 diabetes

  • Text
  • PDF
Abstract

Developing biomarkers to quantitatively monitor disease-specific T cell activity is crucial for assessing type 1 diabetes (T1D) progression and evaluating immunotherapies. This study presents an approach using V gene–targeted sequencing to quantify T cell receptor (TCR) clonotypes as biomarkers for pathogenic T cells in T1D. We identified “public” TCR clonotypes shared among multiple nonobese diabetic (NOD) mice and human organ donors, with a subset expressed exclusively by islet-antigen-reactive T cells in those with T1D. Employing V gene–targeted sequencing of only TCRs containing TRAV16/16D allowed quantitative detection of the public islet-antigen-reactive TCR clonotypes in peripheral blood of NOD mice. Frequencies of these public TCR clonotypes distinguished prediabetic NOD mice from those protected from diabetes. In human islets, public TCR clonotypes identical to preproinsulin-specific clones were exclusively found in T1D donors. This quantifiable TCR sequencing approach uncovered public, disease-specific clonotypes in T1D, providing biomarker candidates to monitor pathogenic T cell frequencies in blood for assessing disease activity and therapeutic response.

Authors

Laurie G. Landry, Kristen L. Wells, Amanda M. Anderson, Kristen R. Miller, Kenneth L. Jones, Aaron W. Michels, Maki Nakayama

×

Figure 2

Reactivity to islet antigens by TCRs composed of public NY8.3 α.

Options: View larger image (or click on image) Download as PowerPoint
Reactivity to islet antigens by TCRs composed of public NY8.3 α.
(A) TCR...
(A) TCR transductants expressing public NY8.3 α along with a pool of 4 or 5 frequent β clonotypes were tested for the response to IGRP peptide 206–214 (blue triangles), insulin B chain peptide 9–23 (black triangles), and a pS3 mimotope of hybrid insulin–chromogranin A peptide (black inverted triangles) in the presence of NOD spleen cells. (B) TCR transductants expressing public NY8.3 along with each β clonotype (B16, B18, B20, B25, or B26) were tested for the response to IGRP peptide 206–214 (blue triangles) and a control TUM peptide (black triangles) in the presence of NOD spleen cells. Cultures without peptides (white triangles) as well as those with anti-CD3 antibody (red triangles) were included as positive and negative controls in each assay. The amounts of IL-2 in culture supernatant were measured by ELISA. Representative results performed in duplicates from 3 repeated experiments are shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts